Literature DB >> 34950995

Preparation and Characterization of Stable Amorphous Glassy Solution of BCS II and IV Drugs.

Sathish Dharani1, Khaldia Sediri1,2, Phillip Cook3, Rajendran Arunagiri3, Mansoor A Khan1, Ziyaur Rahman4.   

Abstract

The focus of the present investigation was to develop amorphous glassy solutions (AGSs) of BCS Class II and IV drugs using sucrose acetate isobutyrate (SAIB). The drugs studied were rifaximin (RFX), dasatinib (DST), aripiprazole (APZ), dolutegravir (DLT), cyclosporine (CYS), itraconazole (ITZ), tacrolimus (TAC), sirolimus (SRL), aprepitant (APT), and carbamazepine (CBZ). AGSs were prepared by dissolving known quantity of the drug in the SAIB at 120 (TAC and APZ), 140 (CYS) or 150 oC (RFX, DST, DLT, ITZ, SRL, APT, and CBZ). They were characterized visually and by NIR, NIR hyperspectroscopy (NIR-H), and XRPD. Stability were determined by exposing open vials to 40 oC/75% RH for a week. AGSs behave like a glassy solid at room temperature and liquified above 60 oC. The solubility of APT, DLT, SRL, APZ, RFX, CBZ, TAC and CYS in SAIB was 0.4±0.0, 1.7±0.4, 1.9±0.0, 21.6±2.6, 36.4±0.9, 76.5±4.0, 115.1±2.3, and 239.0±12.6 mg/g, respectively. NIR, NIR-H, and XRPD data indicated the amorphous nature of the AGSs. Furthermore, AGSs were stable against devitrification on exposure to high temperature and humidity. In summary, SAIB can be employed to develop stable AGSs of poorly soluble drugs to increase dissolution, and oral bioavailability with the addition of hydrophilic excipients.
© 2021. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.

Entities:  

Keywords:  Amorphous; Amorphous glassy solution; Crystalline; Powder X-ray diffraction; Stability; Sucrose acetate isobutyrate

Mesh:

Substances:

Year:  2021        PMID: 34950995     DOI: 10.1208/s12249-021-02198-1

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  40 in total

1.  Biopharmaceutics classification system: the scientific basis for biowaiver extensions.

Authors:  Lawrence X Yu; Gordon L Amidon; James E Polli; Hong Zhao; Mehul U Mehta; Dale P Conner; Vinod P Shah; Lawrence J Lesko; Mei-Ling Chen; Vincent H L Lee; Ajaz S Hussain
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

Review 2.  Emerging trends in the stabilization of amorphous drugs.

Authors:  Riikka Laitinen; Korbinian Löbmann; Clare J Strachan; Holger Grohganz; Thomas Rades
Journal:  Int J Pharm       Date:  2012-04-28       Impact factor: 5.875

3.  Improvement of physicochemical properties of an antiepileptic drug by salt engineering.

Authors:  Ziyaur Rahman; Ahmed S Zidan; Raghu Samy; Vilayat A Sayeed; Mansoor A Khan
Journal:  AAPS PharmSciTech       Date:  2012-05-17       Impact factor: 3.246

4.  Predicting the solubility enhancement of amorphous drugs and related phenomena using basic thermodynamic principles and semi-empirical kinetic models.

Authors:  Peter J Skrdla; Philip D Floyd; Philip C Dell'Orco
Journal:  Int J Pharm       Date:  2019-07-04       Impact factor: 5.875

5.  Determination of tacrolimus crystalline fraction in the commercial immediate release amorphous solid dispersion products by a standardized X-ray powder diffraction method with chemometrics.

Authors:  Ziyaur Rahman; Akhtar Siddiqui; Srikant Bykadi; Mansoor A Khan
Journal:  Int J Pharm       Date:  2014-08-27       Impact factor: 5.875

Review 6.  Cyclodextrins and their pharmaceutical applications.

Authors:  Thorsteinn Loftsson; Dominique Duchêne
Journal:  Int J Pharm       Date:  2006-11-09       Impact factor: 5.875

7.  Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation.

Authors:  Ziyaur Rahman; Ahmed S Zidan; Mansoor A Khan
Journal:  Int J Pharm       Date:  2010-08-27       Impact factor: 5.875

8.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

9.  Assessing the impact of nimodipine devitrification in the ternary cosolvent system through quality by design approach.

Authors:  Ziyaur Rahman; Akhtar Siddiqui; Mansoor A Khan
Journal:  Int J Pharm       Date:  2013-07-31       Impact factor: 5.875

Review 10.  Insoluble drug delivery strategies: review of recent advances and business prospects.

Authors:  Sandeep Kalepu; Vijaykumar Nekkanti
Journal:  Acta Pharm Sin B       Date:  2015-08-24       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.